Now Enrolling
A Phase 2 pivotal trial evaluating tucatinib vs placebo in combination with trastuzumab (Herceptin®) and capecitabine (Xeloda®) in patients with locally advanced or metastatic HER2+ breast cancer, with or without brain metastases
  • Committed to Improving Patients' Lives
  • Innovative Cancer Therapies
Innovative Cancer Therapies - Our pipeline includes tucatinib (ONT-380), a selective small molecule HER2 inhibitor. - Learn More >1 Committed to Improving Patients' Lives - Cascadian Therapeutics is conducting clinical trials in multiple cancer indications. - Learn More >2 Extending Our Reach Through Strategic Partnerships - We leverage partnerships to bring new therapies to more patients, more quickly. - Learn More >3
Pivotal Clinical Trial Now Enrolling
A Pipeline of Innovative Product Candidates
HER2+ Breast Cancer With or Without Brain Metastases
Recent News
Now Enrolling
A Phase 2 pivotal trial evaluating tucatinib vs placebo in combination with trastuzumab (Herceptin®) and capecitabine (Xeloda®) in patients with locally advanced or metastatic HER2+ breast cancer, with or without brain metastases
Pivotal Clinical Trial Now Enrolling
A Pipeline of Innovative Product Candidates
HER2+ Breast Cancer With or Without Brain Metastases